Recommended
More Related Content
Similar to ASCO 2022 Conference
Similar to ASCO 2022 Conference (20)
More from DelveInsight Business Research
More from DelveInsight Business Research (20)
Recently uploaded
Recently uploaded (20)
ASCO 2022 Conference
- 1. ASCO 2022 CONFERENCE DELVEINSIGHT A Quick Overview of Diffuse Large B-Cell Lymphoma (DLBCL) at ASCO 2022 Diffuse Large B Cell Lymphoma is a deadly blood cancer that is the most frequent kind of non-Hodgkin lymphoma (NHL), with over 40,000 new cases diagnosed in Europe each year and another 25,000 in the United States. While the ASCO 2022 annual meeting is approaching, pharma behemoths such as Seagen, Hoffmann-La Roche, and others are seeking the opportunity to share research on several cancers, including Diffuse Large B Cell Lymphoma. Delveinsight has collated all of the future key abstracts while addressing a handful of them, all while preserving a sense of brevity. Abstract Number – 7500 Roche will discuss glofitamab's pivotal Phase II expansion data in patients with R/R DLBCL Cancer. Will there be a follow-up to Polivy's first-in-class CD20xCD3 T- cell engaging bispecific antibody?
- 2. ASCO 2022 CONFERENCE DELVEINSIGHT Glofitamab is part of Roche's larger bispecific antibody development program, which could lead to a new immunotherapy-based treatment option for a variety of blood malignancies. According to recent data, 51.6 percent of patients responded to glofitamab treatment, with 39.4 percent of these patients achieving a complete response, the bulk of which (almost 78 percent) persisting for at least 12 months. Apart from that, the findings suggest that glofitamab could be a good partner for Roche's CD79b-directed ADC Polivy (Polatuzumab Vedotin), which was approved in the EU earlier this week for previously untreated DLBCL and is expected to be a USD 2 billion blockbuster. Based on these findings, glofitamab appears to have the potential to provide a therapeutic benefit. According to the above-mentioned positive outcomes, the upcoming pivotal results are expected to be encouraging, bolstering the promise of glofitamab for patients who have failed several prior lines of therapy and urgently require new therapeutic alternatives. We eagerly await the results of the Phase II trial, which will be presented as an oral abstract session at the ASCO Conference 2022, on June 3, 2022. Abstract Number - 7559 Seagen’s Adcetris (Brentuximab Vedotin), an antibody-drug conjugate for R/R DLBCL Seagen is about to present the Phase III ECHELON-3 study's safety and effectiveness findings. ADCs are a promising class of immunotherapies that have the ability to target tumour cells specifically while also improving the therapeutic index of cytotoxic medicines. Because ADC efficacy and safety have progressed in lockstep with developments in their design, the findings from the ECHELON-3 research will be presented as a poster session at the ASCO Meeting 2022 on June 4, 2022. Conclusion Glofitamab is one step closer to discovering a cure for people with heavily pre- treated diffuse large B-cell lymphoma, which frequently relapses and becomes more aggressive, thanks to new evidence. Furthermore, glofitamab's promise as a new fixed-duration, readily available medication could be critical in improving
- 3. ASCO 2022 CONFERENCE DELVEINSIGHT outcomes for those with this difficult-to-treat cancer who have few other options. The most sought data for this cancer is the expansion results from the upcoming Phase II trial in DLBCL. Apart from that, ADCs will play a critical role in the treatment of patients with R/R DLBCL. As a result, it will be fascinating to follow the outcomes of these two distinct classes of therapy. To Get a Detailed analysis of ASCO Conference 2022 Abstracts, Visit: ASCO 2022 Detailed Coverage Some of the Latest ASCO Abstract 2022 Launched: Can Breyanzi be a hit CAR-T in second-line treatment after failing in the first-line setting for the patients with R/R Large B-cell lymphoma (LBCL)? Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise in Multiple Myeloma during ASCO 2022. Merus’ Zenocutuzumab, a HER2-HER3 Bispecific Antibody, Successfully Targets NRG1 Fusions in Lung and Pancreatic Cancer Trending & Popular Healthcare Market Research Reports Given By DelveInsight Parainfluenza Virus Infection Market Parainfluenza Virus Infection Market Insights, Epidemiology, and Market Forecast- 2032" report deliver an in-depth understanding of the Parainfluenza Virus Infection forecasted epidemiology. Paranasal Sinus Cancer Market Paranasal Sinus Cancer Market Insights, Epidemiology, Market Forecast report delivers an in-depth understanding of the Paranasal Sinus Cancer epidemiology Transient Ischemic Attack Market DelveInsight's Transient Ischemic Attack Market Insights, Epidemiology, and Market Forecast report delivers an in-depth understanding of the Transient Ischemic Attack forecasted epidemiology CAR-T Pipeline
- 4. ASCO 2022 CONFERENCE DELVEINSIGHT CAR-T Pipeline Insights, 2022 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the CAR-T market Plaque Modification Devices Market DelveInsight’s ‘Plaque Modification Devices -Market Insights, Competitive Landscape and Market Forecast - 2027’ report delivers an in-depth understanding of Plaque Modification Devices Sarcopenia Market DelveInsight's Sarcopenia Market Insights, Epidemiology, and Market Forecast- 2032" report delivers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology Hepatic Cirrhosis Market DelveInsight's Hepatic Cirrhosis Market Insights, Epidemiology, and Market Forecast report delivers an in-depth understanding of the Hepatic Cirrhosis, historical and forecasted epidemiology SGLT2 inhibitors Market DelveInsight's SGLT2 inhibitors Market Insights, Epidemiology, and Market Forecast report delivers an in-depth understanding of the SGLT2 inhibitors, historical and forecasted epidemiology Varicose Vein Treatment Devices Market DelveInsight’s ‘Varicose Vein Treatment Devices -Market Insights, Competitive Landscape and Market Forecast - 2027’ report delivers an in-depth understanding of Varicose Vein Treatment Brucellosis Market Brucellosis Market Insights, Market Forecast report delivers an in-depth understanding of the Brucellosis, historical and forecasted epidemiology, and the Brucellosis market trends in 7MM. Orthopedic Splints Market
- 5. ASCO 2022 CONFERENCE DELVEINSIGHT DelveInsight’s ‘Orthopedic Splints -Market Insights, Competitive Landscape and Market Forecast - 2027’ report delivers an in-depth understanding of Orthopedic Splints.. Inflammatory Pain Market Inflammatory Pain Market Insights, Epidemiology, and Market Forecast-2032 report deliver an understanding of the forecasted epidemiology, and the Inflammatory Pain market trends in 7MM. Testicular Neoplasm Market DelveInsight's Testicular Neoplasm Market Insights, Epidemiology, and Market Forecast report delivers an understanding of forecasted epidemiology and the Testicular Neoplasm market trends in 7MM Latest Healthcare Research Reports 2022 By DelveInsight B Cell Chronic Lymphocytic Leukemia Market Medical Marijuana Market Opioid-related Disorders Market Polycystic Kidney Disease Market UK Healthcare Outlook Report Urinary Catheters Market Coronary Microvascular Dysfunction CMD Market Sick Sinus Syndrome Market Oncolytic Virus Cancer Therapy Pipeline Pelvic Organ Prolapse Market B-Cell Maturation Antigen Targeted Therapies Market Asperger Syndrome Market Tuberculosis Market Sly Syndrome Market Membranous Nephropathy Market Proteus Syndrome Market Stem Cell Market About Us
- 6. ASCO 2022 CONFERENCE DELVEINSIGHT DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions. Contact Us Yash info@delveinsight.com